Clinical characteristicsa
| Parameter | Group (n = 23) | IPH(+) (n = 11) | IPH(–) (n = 12) | P |
|---|---|---|---|---|
| Participant characteristics | ||||
| Male | 21 (91.3) | 11 (100.0) | 10 (83.3) | .48 |
| Age (yr) | 66.2 (SD, 8.0) | 71.2 (SD, 7.6) | 61.5 (SD, 5.2) | .002 |
| BMI (kg/m2) | 31.7 (SD, 7.3) | 33.4 (SD, 7.0) | 30.1 (SD, 7.5) | .30 |
| Right-handed | 20 (87.0) | 9 (81.8) | 11 (91.7) | .59 |
| Comorbidities | ||||
| Hyperlipidemia | 18 (78.3) | 10 (90.9) | 8 (66.7) | .32 |
| Hypertension | 14 (60.9) | 6 (54.6) | 8 (66.7) | .68 |
| Current smoker | 4 (17.4) | 0 (0.0) | 4 (33.3) | .09 |
| Prior smoker | 14 (60.9) | 8 (72.7) | 6 (50.0) | .40 |
| Renal insufficiency | 1 (4.4) | 1 (9.1) | 0 (0.0) | .48 |
| Diabetes | 11 (47.8) | 6 (54.6) | 5 (41.7) | .54 |
| Ischemic stroke and WM disease | ||||
| Ischemic stroke | 7 (30.4) | 3 (27.3) | 4 (33.3) | 1.00 |
| Postintervention stroke | 0 (0.0) | 0 (0.0) | 0 (0.0) | – |
| WM disease ratingb | 1.6 (SD, 1.2) | 1.9 (SD, 1.4) | 1.4 (SD, 1.0) | .36 |
| Medications | ||||
| Statin | 19 (82.6) | 9 (81.8) | 10 (83.3) | 1.00 |
| Antihypertensive | 13 (56.5) | 6 (54.6) | 7 (58.3) | 1.00 |
| Antiplatelet | 15 (65.2) | 7 (63.6) | 8 (66.7) | 1.00 |
| Anticoagulation | 3 (13.4) | 3 (27.3) | 0 (0.0) | .09 |